Recro shares crater after CRL for analgesic

Recro Pharma Inc. (NASDAQ:REPH) lost 55% to $5.63 on May 24 after FDA issued a complete response

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE